MX2018010132A - Inhibidores peptidicos de los canales de calcio. - Google Patents

Inhibidores peptidicos de los canales de calcio.

Info

Publication number
MX2018010132A
MX2018010132A MX2018010132A MX2018010132A MX2018010132A MX 2018010132 A MX2018010132 A MX 2018010132A MX 2018010132 A MX2018010132 A MX 2018010132A MX 2018010132 A MX2018010132 A MX 2018010132A MX 2018010132 A MX2018010132 A MX 2018010132A
Authority
MX
Mexico
Prior art keywords
calcium channels
calcium
peptide inhibitors
calcium influx
channels
Prior art date
Application number
MX2018010132A
Other languages
English (en)
Spanish (es)
Inventor
Tarran Robert
Wu Tongde
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of MX2018010132A publication Critical patent/MX2018010132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2018010132A 2016-02-22 2017-02-22 Inhibidores peptidicos de los canales de calcio. MX2018010132A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662298204P 2016-02-22 2016-02-22
PCT/US2017/018840 WO2017147128A1 (en) 2016-02-22 2017-02-22 Peptide inhibitors of calcium channels

Publications (1)

Publication Number Publication Date
MX2018010132A true MX2018010132A (es) 2019-06-06

Family

ID=59685595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010132A MX2018010132A (es) 2016-02-22 2017-02-22 Inhibidores peptidicos de los canales de calcio.

Country Status (9)

Country Link
US (1) US10894811B2 (enExample)
EP (1) EP3419994B1 (enExample)
JP (1) JP2019512216A (enExample)
AU (1) AU2017222450A1 (enExample)
BR (1) BR112018017144A2 (enExample)
ES (1) ES2979122T3 (enExample)
IL (1) IL261265A (enExample)
MX (1) MX2018010132A (enExample)
WO (1) WO2017147128A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3046361A1 (en) * 2016-12-13 2018-06-21 Spyryx Biosciences, Inc. Saline formulations of splunc1 peptides
JP2024511119A (ja) * 2021-03-22 2024-03-12 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 修飾されたペプチド模倣薬および使用方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
JP2627899B2 (ja) 1987-08-19 1997-07-09 株式会社 ビタミン研究所 遺伝子封入リポソームの製法
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69031305T2 (de) 1989-11-03 1998-03-26 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
PT956001E (pt) 1996-11-12 2012-12-06 Univ California Preparação de formulações estáveis de complexos do tipo lípido-ácido nucleico para uma entrega eficiente in vivo
EP1224471B1 (en) * 2000-02-24 2003-11-26 Oxford GlycoSciences (UK) Limited Dpi-6, a therapeutic biomarker in neurological disorders
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
WO2005056045A1 (en) * 2003-12-04 2005-06-23 The University Of Iowa Research Foundation Methods and compositions related to plunc polypeptides
DE102004031579B4 (de) * 2004-06-29 2012-12-27 Forschungsverbund Berlin E.V. Peptide zur Inhibition der Interaktion von Proteinkinase A und Proteinkinase A-Ankerproteinen, diese umfassendes Nukleinsäuremolekül, Vektor, Wirtszelle, gegen diese gerichtetes Erkennungsmolekül, diese enthaltende pharmazeutische Zusammensetzung, diese enthaltender Kit und deren Verwendung
WO2013043720A1 (en) * 2011-09-20 2013-03-28 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins

Also Published As

Publication number Publication date
AU2017222450A1 (en) 2018-09-27
BR112018017144A2 (pt) 2019-01-15
IL261265A (en) 2018-10-31
ES2979122T3 (es) 2024-09-24
EP3419994B1 (en) 2024-05-08
US10894811B2 (en) 2021-01-19
EP3419994C0 (en) 2024-05-08
WO2017147128A1 (en) 2017-08-31
JP2019512216A (ja) 2019-05-16
US20190062386A1 (en) 2019-02-28
EP3419994A1 (en) 2019-01-02
EP3419994A4 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
CL2020002019A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
MX2017003247A (es) Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
EA033325B1 (ru) Ингибиторы бромодомена
MX2020011749A (es) Composiciones y metodos para modular la expresion de pkk.
MX380414B (es) Polipeptidos biparatopicos que antagonizan la señalizacion wnt en celulas tumorales.
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
NZ746609A (en) Ilt7 binding molecules and methods of using the same
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
ZA202002936B (en) Phenoxy acids for the treatment of neuromuscular disorders
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
PH12017500613A1 (en) Improved peptide inhibitors of sodium channels
MX2018010132A (es) Inhibidores peptidicos de los canales de calcio.
WO2018125799A3 (en) Metalloenzyme inhibitor compounds
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
GB2574747A (en) Use of lambda interferons in the treatment of obesity-related disorders and related diseases
AU2018275270A1 (en) Peptide PAC1 antagonists
MX2018003040A (es) Metodos para el tratamiento de formas recurrentes de esclerosis multiple.